Comparative Study of Additive IOP Lowering Effects and Safety Profile of Ripasudil 0.4% Combined with Timolol 0.5% and Ripasudil 0.4% Combined with Bimatoprost 0.03% In Primary Open Angle Glaucoma in Indian Eyes

Abstract: Introduction: IOP lowering is the mainstay of glaucoma treatment. Beta-adrenergic drugs and prostaglandins are some of the commonly used topical medications for this purpose. Ripasudil hydrochloride hydrate, a new Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor has also emerged as an effective alternative, however, its efficacy as adjuvant to currently used topical medications has not been studied. Aim: To study additive IOP lowering effects and safety profile of the rho-kinase inhibitor (Ripasudil) combined with Timolol or Bimatoprost in Primary Open Angle Glaucoma (POAG). Materials and Methods: A total of 80 POAG patients were allocated to four study groups ? TM (n=20) receiving topical 0.5% Timolol, TMR (n=20) 0.5% Timolol + 0.4% Ripusadil, BP (n=20) receiving topical 0.03% Bimatoprost and BPR (n=20) ? 0.03% Bimatoprost + 0.4% Ripusadil. Change in IOP from baseline was measured at 4, 6 and 8 week follow-ups. Result: At last follow-up, mean decline in IOP as compared to baseline was 6.21?1.56, 8.44?1.55, 6.08?1.54 and 8.74?1.53 mmHg respectively in TM, TMR, BP and BPR groups respectively (p<0.001). No major adverse effect was seen in any study group. Conclusion: Addition of Ripusadil to conventionally used topical hypotensive agents added to their IOP lowering efficacy without additional burden of adverse effects.

Keywords: Ripusadil, Primary open angle glaucoma (POAG), Prostaglandin, Beta-adrenergic

Edition: Volume 12 Issue 12, December 2023,

Pages: 748 - 751